• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

调强放疗时代同步放化疗与单纯放疗治疗局部晚期鼻咽癌的Meta分析

Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: a meta-analysis.

作者信息

He Yan, Guo Tao, Guan Hui, Wang Jingjing, Sun Yu, Peng Xingchen

机构信息

Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, China.

出版信息

Cancer Manag Res. 2018 Jun 6;10:1419-1428. doi: 10.2147/CMAR.S160469. eCollection 2018.

DOI:10.2147/CMAR.S160469
PMID:29922086
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5995285/
Abstract

PURPOSE

In this study, we attempted to compare the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with radiotherapy alone (RT) for locoregionally advanced nasopharyngeal carcinoma (LANPC) in the era of intensity-modulated radiotherapy (IMRT) by meta-analysis.

MATERIALS AND METHODS

We searched databases, and all randomized controlled trials meeting the inclusion criteria were utilized for a meta-analysis with RevMan 5.3 based on the Cochrane methodology.

RESULTS

Fifteen studies were found suitable based on the inclusion criteria. CCRT not only significantly improved the overall response rate (risk ratio [RR]=0.53, 95% CI 0.43-0.66) and the complete response rate (RR=0.60, 95% CI 0.51-0.71) but also contributed to longer overall survival. The incidence of grade 3-4 adverse events from CCRT group increased in hematologic toxicity (RR 2.25, 95% CI 1.54-3.29), radiation-induced oral mucositis (RR 1.64, 95% CI 1.14-2.35), and radiodermatitis (RR 1.80, 95% CI 1.13-2.88).

CONCLUSION

Compared with IMRT alone, CCRT provided survival benefit with acceptable toxicity in patients with LANPC. However, we need multicenter randomized controlled trials and long-term follow-up to evaluate the eventual efficacy and toxicity of concurrent chemotherapy plus IMRT.

摘要

目的

在本研究中,我们试图通过荟萃分析比较调强放疗(IMRT)时代同步放化疗(CCRT)与单纯放疗(RT)治疗局部晚期鼻咽癌(LANPC)的疗效和毒性。

材料与方法

我们检索了数据库,并根据Cochrane方法,使用RevMan 5.3对所有符合纳入标准的随机对照试验进行荟萃分析。

结果

根据纳入标准,发现15项研究合适。CCRT不仅显著提高了总缓解率(风险比[RR]=0.53,95%CI 0.43 - 0.66)和完全缓解率(RR=0.60,95%CI 0.51 - 0.71),还有助于延长总生存期。CCRT组3 - 4级不良事件的发生率在血液学毒性(RR 2.25,95%CI 1.54 - 3.29)、放射性口腔黏膜炎(RR 1.64,95%CI 1.14 - 2.35)和放射性皮炎(RR 1.80,95%CI 1.13 - 2.88)方面有所增加。

结论

与单纯IMRT相比,CCRT为LANPC患者提供了生存获益且毒性可接受。然而,我们需要多中心随机对照试验和长期随访来评估同步化疗联合IMRT的最终疗效和毒性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/858d/5995285/80d0f940e9e4/cmar-10-1419Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/858d/5995285/3ec126122f6e/cmar-10-1419Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/858d/5995285/586c1e2469a1/cmar-10-1419Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/858d/5995285/5caf7530b964/cmar-10-1419Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/858d/5995285/80d0f940e9e4/cmar-10-1419Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/858d/5995285/3ec126122f6e/cmar-10-1419Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/858d/5995285/586c1e2469a1/cmar-10-1419Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/858d/5995285/5caf7530b964/cmar-10-1419Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/858d/5995285/80d0f940e9e4/cmar-10-1419Fig5.jpg

相似文献

1
Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: a meta-analysis.调强放疗时代同步放化疗与单纯放疗治疗局部晚期鼻咽癌的Meta分析
Cancer Manag Res. 2018 Jun 6;10:1419-1428. doi: 10.2147/CMAR.S160469. eCollection 2018.
2
Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.局部晚期鼻咽癌诱导化疗加 IMRT 与诱导化疗加基于 IMRT 的同期放化疗的回顾性队列研究。
J Cancer Res Clin Oncol. 2019 Jul;145(7):1857-1864. doi: 10.1007/s00432-019-02925-z. Epub 2019 May 6.
3
Radiation-induced acute injury of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a prospective cohort study.诱导化疗后同期放化疗中调强放疗与三维适形放疗治疗局部晚期鼻咽癌的急性放射损伤:前瞻性队列研究。
Sci Rep. 2021 Apr 8;11(1):7693. doi: 10.1038/s41598-021-87170-6.
4
Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.新辅助化疗联合调强放疗与同步放化疗联合辅助化疗治疗局部晚期鼻咽癌的回顾性对照研究
Chin J Cancer. 2016 Jan 6;35:2. doi: 10.1186/s40880-015-0076-9.
5
Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.联合肿瘤反应和个体化风险评估:调强放疗时代局部晚期鼻咽癌同期化疗适应性的潜力。
Radiother Oncol. 2021 Feb;155:56-64. doi: 10.1016/j.radonc.2020.10.005. Epub 2020 Oct 8.
6
Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.常规分割同步放化疗与单纯超分割放疗在局部晚期头颈部鳞状细胞癌确定性治疗中的系统评价和荟萃分析
Clin Oncol (R Coll Radiol). 2016 Jan;28(1):50-61. doi: 10.1016/j.clon.2015.09.002. Epub 2015 Oct 9.
7
Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.序贯诱导化疗加调强放疗与同期放化疗治疗局部晚期鼻咽癌:一项 II 期、单中心、随机、非劣效性试验的三年报告。
Cancer Med. 2021 Jun;10(12):3886-3895. doi: 10.1002/cam4.3936. Epub 2021 May 6.
8
Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma.调强放疗同步推量治疗局部晚期鼻咽癌。
Radiat Oncol. 2014 Feb 18;9:56. doi: 10.1186/1748-717X-9-56.
9
The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.多西他赛、顺铂和氟尿嘧啶(TPF)为基础的诱导化疗联合同期放化疗治疗局部晚期鼻咽癌的疗效和安全性:一项荟萃分析。
Clin Transl Oncol. 2020 Mar;22(3):429-439. doi: 10.1007/s12094-019-02142-7. Epub 2019 Jun 4.
10
Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy.采用调强放疗联合每周一次顺铂同步治疗,加或不加新辅助化疗,治疗局部区域晚期鼻咽癌。
Radiat Oncol J. 2015 Jun;33(2):98-108. doi: 10.3857/roj.2015.33.2.98. Epub 2015 Jun 30.

引用本文的文献

1
Chinese clinical practice guidelines for the prevention and treatment of radiation-induced dermatitis.放射性皮炎防治中国临床实践指南
Precis Radiat Oncol. 2023 Sep 10;7(3):160-172. doi: 10.1002/pro6.1208. eCollection 2023 Sep.
2
Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?早期和局部晚期鼻咽癌治疗:从现在到未来,我们在哪里,我们要去哪里?
Curr Treat Options Oncol. 2023 Jul;24(7):845-866. doi: 10.1007/s11864-023-01083-2. Epub 2023 May 5.
3
Quality assessment of PBM protocols for oral complications in head and neck cancer patients: part 2.

本文引用的文献

1
T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.T4/N2 分期鼻咽癌在调强放疗时代可从同步化疗中获益。
Oncotarget. 2016 Dec 6;7(49):81918-81925. doi: 10.18632/oncotarget.11981.
2
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
3
Meta-analysis of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.
头颈部癌症患者口腔并发症的PBM方案质量评估:第2部分。
Support Care Cancer. 2023 Apr 28;31(5):306. doi: 10.1007/s00520-023-07749-9.
4
Concurrent chemoradiotherapy versus radiotherapy alone for stage II nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.调强放疗时代局部晚期鼻咽癌同期放化疗对比单纯放疗
Eur Arch Otorhinolaryngol. 2023 Jul;280(7):3097-3106. doi: 10.1007/s00405-023-07943-9. Epub 2023 Apr 20.
5
Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy.预测接受化疗或放疗的恶性肿瘤合并 HIV 感染患者中性粒细胞减少症的因素。
Asian Pac J Cancer Prev. 2022 Feb 1;23(2):445-450. doi: 10.31557/APJCP.2022.23.2.445.
6
Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options.鼻咽癌:治疗方案中的临床成果与考量
Front Oncol. 2021 Nov 29;11:635737. doi: 10.3389/fonc.2021.635737. eCollection 2021.
7
SP1-induced AFAP1-AS1 contributes to proliferation and invasion by regulating miR-497-5p/CELF1 pathway in nasopharyngeal carcinoma.SP1 诱导的 AFAP1-AS1 通过调节 miR-497-5p/CELF1 通路促进鼻咽癌的增殖和侵袭。
Hum Cell. 2021 Mar;34(2):491-501. doi: 10.1007/s13577-020-00475-y. Epub 2021 Jan 5.
8
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1).接受曲妥珠单抗-美坦新偶联物(T-DM1)同步治疗患者的放射性皮炎。
Clin Transl Radiat Oncol. 2020 Jul 3;24:99-101. doi: 10.1016/j.ctro.2020.06.013. eCollection 2020 Sep.
9
Patterns of oral mucositis in advanced oral squamous cell carcinoma patients managed with prophylactic photobiomodulation therapy-insights for future protocol development.预防性光生物调节疗法管理下的晚期口腔鳞状细胞癌患者口腔黏膜炎的模式——对未来方案制定的启示。
Lasers Med Sci. 2021 Mar;36(2):429-436. doi: 10.1007/s10103-020-03091-2. Epub 2020 Jul 5.
10
Efficacy and safety of carbon-ion radiotherapy for the malignant melanoma: A systematic review.碳离子放疗治疗恶性黑色素瘤的疗效和安全性:系统评价。
Cancer Med. 2020 Aug;9(15):5293-5305. doi: 10.1002/cam4.3134. Epub 2020 Jun 10.
同步放化疗治疗局部晚期鼻咽癌的Meta分析
J Cancer Res Ther. 2015 Oct;11 Suppl 2:C191-5. doi: 10.4103/0973-1482.168183.
4
Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis.调强放射治疗与二维放疗或三维适形放疗治疗鼻咽癌的系统评价和荟萃分析
Oral Oncol. 2015 Nov;51(11):1041-1046. doi: 10.1016/j.oraloncology.2015.08.005. Epub 2015 Aug 18.
5
Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials.与单纯放疗相比,同步放化疗与鼻咽癌患者更高的严重晚期毒性发生率相关:一项基于随机对照试验的荟萃分析。
Radiat Oncol. 2015 Mar 26;10:70. doi: 10.1186/s13014-015-0377-9.
6
Global cancer statistics, 2012.全球癌症统计数据,2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
7
Impact of intensity-modulated radiotherapy on nasopharyngeal carcinoma: Validation of the 7th edition AJCC staging system.调强放射治疗对鼻咽癌的影响:美国癌症联合委员会(AJCC)第7版分期系统的验证
Oral Oncol. 2015 Mar;51(3):254-9. doi: 10.1016/j.oraloncology.2014.10.012. Epub 2014 Nov 6.
8
Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities.调强放疗后T4期鼻咽癌的更新报告:生存及治疗毒性分析
Oral Oncol. 2015 Feb;51(2):190-4. doi: 10.1016/j.oraloncology.2014.11.009. Epub 2014 Nov 26.
9
Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.868例鼻咽癌患者调强放疗的长期疗效:生存及治疗毒性分析
Radiother Oncol. 2014 Mar;110(3):398-403. doi: 10.1016/j.radonc.2013.10.020. Epub 2013 Nov 11.
10
A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma.一项前瞻性、随机对照研究比较了调强放疗与常规二维放疗治疗鼻咽癌的疗效和毒性。
Radiother Oncol. 2012 Sep;104(3):286-93. doi: 10.1016/j.radonc.2012.08.013. Epub 2012 Sep 17.